

CURRICULUM VITAE

NAME Kenneth B. Sloan

DATE OF BIRTH June 24, 1943

PLACE OF BIRTH St. Louis, Missouri

ADDRESS 3551 N.W. 23rd Place, Gainesville, Florida 32605

TELEPHONE Home: (352) 375-4389 Work: (352) 846-1957

EDUCATION

1965 A.B. Degree, Rockhurst College, Kansas City, Missouri

1969 Ph.D. Degree, University of Missouri, Columbia, Missouri

PROFESSIONAL EXPERIENCE

1995 - Present Professor, Medicinal Chemistry Department
College of Pharmacy, University of Florida
Gainesville, Florida.

1985 - 1995 Associate Professor, Medicinal Chemistry
Department, College of Pharmacy, University
of Florida, Gainesville, Florida.

1980 - 1985 Assistant Professor, Medicinal Chemistry Department, College of
Pharmacy, University of Florida, Gainesville, Florida.

1972 - 1980 Senior Research Chemist, INTERx Research Corporation,
Lawrence, Kansas. Supervisor: Dr. Takeru Higuchi (deceased)

1971 - 1972 Instructor in Organic Chemistry, University of Virginia.
Charlottesville, Virginia. Supervisor: Dr. Richard Sundberg

1969 - 1971 Postdoctoral appointment in Organic Chemistry, University of
Minnesota, Minneapolis, Minnesota. Supervisor: Dr. William
Parham (deceased).

1965 - 1969 Graduate Student in Organic Chemistry, University of Missouri,
Columbia, Missouri. Thesis supervisor: Dr. Norman Rabjohn
(deceased).

HONORS AND PROFESSIONAL MEMBERSHIPS

NDEA Graduate Fellowship, 1965-1968

Shell Fellowship, 1968-1969

Sigma Xi

Phi Lambda Upsilon

Member, American Chemical Society, 1965 to present

Member, American Pharmaceutical Association, Academy of Pharmaceutical
Research and Science, 1979 to present

Member, American Association of Colleges of Pharmacy, 1983 to present

Sustaining Charter Member, American Association of Pharmaceutical
Scientists, 1986 to present

PUBLICATIONS

Thesis title, "A Study of Some Reactions of Aliphatic Methylhydrazones and Related Compounds."

JOURNAL ARTICLES

1. Rabjohn, N., and Sloan, K.B., "Alkylidenebis-1-methyl-2-alkylidenehydrazines as Intermediates in the Reaction of Methylhydrazine with Aliphatic Aldehydes," J. Heterocyclic Chem., 6 (1969) 187-190.
2. Sloan, K.B., and Rabjohn, N., "The Synthesis of Alkyl Substituted 2-Pyrazolines by the Reaction of Acids with Hydrazine Derivatives," J. Heterocyclic Chem., 7 (1970) 1272-1281.
3. Parham, W.E., and Sloan, K.B., "The Reaction of Heterocycle N-Oxides with Benzimidoyl Chloride," Tetrahedron Letters, (1971) 1947-1950.
4. Parham, W.E., Sloan, K.B., and Biasotti, B., "Stereoselective Synthesis of 2,4-Bridged Pyridinophanes," Tetrahedron, 27 (1971) 5767-5770.
5. Parham, W.E., Sloan, K.B., Reddy, K., and Olson, P.E., "Reaction of Aromatic Amine Oxides with Acid Halides, Sulfonyl Halides and Phosphorous Oxychloride. The Stereochemical Configuration of Substituents in the 1-Position of 12, 13-Benzo-16-chloro[10](2,4)pyridinophanes," J. Org. Chem., 38 (1973) 927-931.
6. Sundberg, R.J., and Sloan, K.B., "Acid-Promoted Aromatic Substitution Processes in Photochemical and Thermal Decompositions of Aryl Azides," J. Org. Chem., 38 (1973) 2052-2057.
7. Parham, W.E., Olson, P.E., Reddy, Ratnammal K., and Sloan, K.B., "1,2-Bridged Aromatic Systems IX. Reactions of Syn- and Anti-Derivatives of 1-Substituted 12,13-Benzo-16-chloro[10](2,4) pyridinophanes," J. Org. Chem., 39 (1974) 172-176.
8. Repta, A.J., Rawson, B.J., Shaffer, Richard D., Sloan, K.B., Bodor, N., and Higuchi, T., "Rational Development of a Soluble Pro-Drug of a Cytotoxic Nucleoside: Preparation and Properties of Arabinosyladenine 5-Formates," J. Pharm. Sci., 64 (1975) 392-396.
9. Sloan, K.B., and Bodor, N., "O-Acylation of Acidic Methylene Compounds," J. Org. Chem., 41 (1976) 165-166.

10. Bodor, N., Sloan, K.B., Higuchi, T., and Sasahara, K., "Improved Delivery Through Biological Membranes, Part IV. Prodrugs of L-DOPA," J. Med. Chem., 20 (1977) 1435-1445.
11. Sloan, K.B., Bodor, N., Higuchi, T., Little, R., and Wu, M., "Micellar Acceleration of Phosphorylation of Hydroxamic Acids: The Effect of Chain Length and Intramolecular Tertiary Amino Group," J. Chem. Research(s), 20 (1977) 290-291.
12. Bodor, N., Sloan, K.B., Kuo, N., and Higuchi, T., "Controlled Delivery of Theophylline. The Chemistry of Mono- and Bis-7-Theophylline Acylates," J. Pharm. Sci., 67 (1978) 1045-1050.
13. Sloan, K.B., Little R., and Bodor, N., "Acid Catalyzed Rearrangements of the Dihydroxyacetone Side Chain in Steroids during Ketal Exchange," J. Org. Chem., 43 (1978) 3405-3408.
14. Sloan, K.B., Bodor, N., and Zupan, J., "Acylation of the 4,5- and 5,6-Double Bond Isomers of Spiro-3-Steroidal Thiazolidines," Tetrahedron, 37 (1981) 3463-3466.
15. Sloan, K.B., Bodor, N., and Little, R., "¹³C NMR Spectroscopy of 4,5- and 5,6-Double-Bond Isomers of Spiro-3-Steroidal Ketone Derivatives," Tetrahedron, 37 (1981) 3467-3471.
16. Bodor, N., Sloan, K.B., Little, R., Selk, S., and Caldwell, L., "Soft Drugs 4. 3-Spirothiazolidines of Hydrocortisone and Its Derivatives," Int. J. Pharm., 10 (1982) 307-321.
17. Bodor, N., and Sloan, K.B., "Soft Drugs 5. Thiazolidine Type Derivatives of Progesterone and Testosterone," J. Pharm. Sci., 71 (1982) 514-520.
18. Sloan, K.B., and Bodor, N., "Hydroxymethyl and Acyloxymethyl Prodrugs of Theophylline: Enhanced Delivery of Polar Drugs Through Skin," Int. J. Pharm., 12 (1982) 299-313.
19. Sloan, K.B., Hashida, M., Alexander, J., Bodor, N., and Higuchi, T., "Prodrugs of 6-Thiopurines: Enhanced Delivery Through the Skin," J. Pharm. Sci., 72 (1983) 372-378.
20. Bodor, N., and Sloan, K.B., "Improved Delivery Through Biological Membranes XI: The Effect of the Incorporation of Biphasic Solubilizing Groups into Prodrugs of Steroids," Int. J. Pharm., 15 (1983) 235-250.

21. Sloan, K.B., and Koch, S.A.M., "The Effect of Nucleophilicity and Leaving Group Ability on the S_N2 Reactions of Amines with (Acyloxy)alkyl α -Halides: A Product Distribution Study," J. Org. Chem., 48 (1983) 635-640.
22. Sloan, K.B., and Koch, S.A.M., "The Reaction of (Acyloxy)alkyl α -Halides with Phenols: The Effect of Nucleofugicity and Nucleophilicity on Product Distribution," J. Org. Chem., 48 (1983) 3777-3783.
23. Bodor, N., Sloan, K.B., Kaminski, J.J., Shih, C., and Pogany, S., "A Convenient Synthesis of (Acyloxy)alkyl α -Ethers of Phenols," J. Org. Chem., 48 (1983) 5280-5284.
24. Varian, S.A., Schuller, S., Sloan, K.B., and Stella, V.J., "Phenytoin Prodrug III: Water Soluble Prodrugs for Oral and/or Parenteral Use," J. Pharm. Sci., 73 (1984) 1068-1073.
25. Sloan, K.B., Selk, S., Haslam, J., Caldwell, L., and Shaffer, R., "Acyloxyamines as Prodrugs of Anti-Inflammatory Carboxylic Acids for Improved Delivery Through Skin," J. Pharm. Sci., 73 (1984) 1734-1737.
26. Sloan, K.B., Koch, S.A.M., and Siver, K.G., "Mannich Base Derivatives of Theophylline and 5-Fluorouracil: Syntheses, Properties and Topical Delivery Characteristics," Int. J. Pharm., 21 (1984) 251-264.
27. Sloan, K.B., and Siver, K.G., "The Aminomethylation of Adenine, Cytosine and Guanine," Tetrahedron, 40 (1984) 3997-4001.
28. Sloan, K.B., and Koch, S.A.M., "Further Reactions of 3-Hydroxy-1(3H)-Isobenzofuranone With Amines," J. Het. Chem., 22 (1985) 429-432.
29. James, M.O., and Sloan, K.B., "Structural Features of Imidazole Derivatives Which Enhance Styrene Oxide Hydrolase Activity in Rat Hepatic Microsomes," J. Med. Chem., 28 (1985) 1120-1124.
30. O'Neal, J., Sloan, K.B., and Schulman, S.G., "Substrate-Labeled Fluorescence Immunoassay of Phenytoin," Int. J. Pharm. Biomed. Anal., 4 (1986) 103-106.
31. Sloan, K.B., Koch, S.A.M., Siver, K.G., and Flowers, F.P., "The Use of Solubility Parameters of Drug and Vehicles to Predict Flux," J. Invest. Dermatol., 87 (1986) 244-252.
32. Sloan, K.B., Siver, K.G., and Koch, S.A.M., "The Effect of Vehicles on the Diffusion of Salicylic Acid Through Hairless Mouse Skin," J. Pharm. Sci., 75 (1986) 744-749.

33. Koch, S.A.M., and Sloan, K.B., "N-Mannich Base Derivatives of 5-Fluorocytosine: A Prodrug Approach to Improve Topical Delivery," Int. J. Pharm., 35 (1987) 243-252.
34. Waranis, R.P., Siver, K.G., and Sloan, K.B., "The Solubility Parameter of Vehicles as a Predictor of Vehicle Effects on the Diffusion of 6-Mercaptopurine," Int. J. Pharm., 36 (1987) 211-222.
35. Sherertz, E.F., Sloan, K.B., and McTiernan, R.G., "Use of Theoretical Partition Coefficients Determined from Solubility Parameters to Predict Permeability Coefficients for 5-Fluorouracil," J. Invest. Dermatol., 89 (1987) 147-151.
36. Sherertz, E.F., Sloan, K.B., and McTiernan, R.G., "Effect of Skin Pretreatment with Vehicle Alone or Drug in Vehicle on Flux of a Subsequently Applied Drug: Results of Hairless Mouse Skin Diffusion Cell Studies," J. Invest. Dermatol., 89 (1987) 249-252.
37. Koch, S.A.M., and Sloan, K.B., "N-Mannich Base Prodrugs of 5-Iodo-2'-deoxycytidine as Topical Delivery Enhancers," Pharm. Res., 4 (1987) 317-320.
38. Waranis, R.P., and Sloan, K.B., "The Effects of Vehicle and Prodrug Properties and Their Interactions on the Delivery of 6-Mercaptopurine Through Skin: Bisacyloxymethyl-6-mercaptopurine Prodrugs," J. Pharm. Sci., 76 (1987) 587-595.
39. Waranis, R.P., and Sloan, K.B., "Effects of Vehicles and Prodrug Properties and Their Interactions on the Delivery of 6-Mercaptopurine Through Skin: S⁶-Acyloxymethyl-6-mercaptopurine Prodrugs," J. Pharm. Sci., 77 (1988) 210-215.
40. Sherertz, E.F., and Sloan, K.B., "Percutaneous Penetration of Squaric Acid and Its Esters in Hairless Mouse and Human Skin *in vitro*," Arch. Dermatol. Res., 280 (1988) 57-60.
41. Sloan, K.B., Sherertz, E.F., and McTiernan, R.G., "The Effect of Structure of Mannich Base Prodrugs on Their Ability to Deliver Theophylline and 5-Fluorouracil Through Hairless Mouse Skin," Int. J. Pharm., 44 (1988) 87-96.
42. Siver, K.G., Sloan, K.B., Waranis, R.P., and Saab, A.N., "Hydroxymethylation and Aminomethylation of 6-Mercaptopurine and Its Derivatives," J. Het. Chem., 25 (1988) 1077-1081.
43. Siver, K.G., and Sloan, K.B., "The Effect of Structure of Mannich Base Prodrugs of 6-Mercaptopurine on their ability to deliver 6-Mercaptopurine through Hairless Mouse Skin," Int. J. Pharm., 48 (1988) 195-206.
44. Sloan, K.B., "Prodrugs for Dermal Delivery," Ad. Drug Delivery Rev., 3 (1989) 67-101.

45. Saab, A.N., and Sloan, K.B., "The Effect of Aminomethyl (N-Mannich Base) Derivatives on the Ability of S⁶-Pivaloyloxymethyl-6-mercaptopurine Prodrug to Deliver 6-Mercaptopurine through Skin," Int. J. Pharm., 57 (1989) 253-261.
46. Siver, K.G., and Sloan, K.B., "Alkylation of 6-Mercaptopurine (6-MP) with N-Alkyl-N-Alkoxy-carbonylamino-methyl Chlorides: S⁶-(N-Alkyl-N-Alkoxy-carbonyl) aminomethyl-6-MP Prodrug Structure Effect on the Dermal Delivery of 6-MP," J. Pharm. Sci., 79 (1990) 66-73.
47. Saab, A.N., Sloan, K.B., Beall, H.D., and Villanueva, R., "The Effect of Aminomethyl (N-Mannich Base) Derivatization on the Ability of S⁶-Acetyloxymethyl-6-mercaptopurine Prodrug to Deliver 6-mercaptopurine through Hairless Mouse Skin," J. Pharm. Sci., 79 (1990) 1099-1104.
48. Sherertz, E.F., Sloan, K.B., and McTiernan, R.G., "Transdermal Delivery of 5-Fluorouracil through Skin of Hairless Mice and Humans in vitro: A comparison of the Effect of Formulations and Prodrug," Arch. Dermatol. Res., 282 (1990) 463-468.
49. Sloan, K.B., Sherertz, E.F., and McTiernan, R.G., "The Effect of 5-FU on Inhibition of Epidermal DNA Synthesis *in vivo*: A Comparison of the Effect of Formulations and a Prodrug of 5-FU," Arch. Dermatol. Res., 282 (1990) 484-486.
50. Sloan, K.B., Beall, H.D., Villanueva, R., and Weimar, W.R., "The Effect of Receptor Phase Composition on the Permeability of Hairless Mouse Skin in Diffusion Cell Experiments," Int. J. Pharm., 73 (1991) 97-104.
51. Getz, J.J., Pranker, R.J., and Sloan, K.B., "Mechanism of Hydrolysis of Benzamidomethyl Derivatives of Phenols and its Implications for Prodrug Design," J. Org. Chem., 57 (1992) 1702-1706.
52. Moelands, D., Karnik, N.A., Pranker, R.J., Sloan, K.B., Stone, H.W., Perrin, J.H., "Microcalorimetric Study of the Interactions of Aspartame with β -Cyclodextrin and Hydroxypropyl- β -Cyclodextrin: The Anomalous Heat of Dilution of the Latter," Int. J. Pharm., 86 (1992) 263-265.
53. Pranker, R.J., Stone, H.W., Sloan, K.B., Perrin, J.H., "Degradation of Aspartame in Acidic Aqueous Media and its Stabilization by Complexation with Cyclodextrins or Modified Cyclodextrins," Int. J. Pharm., 88 (1992) 189-199.
54. Sloan, K.B. and Beall, H.D., "The Prodrug Option for Increasing Topical Delivery," Cosmet. Toiletries, 108 (April, 1993) 85-92.

55. Beall, H.D., Pranker, R.J., Todaro, L.J., Sloan, K.B., "Structure of 3-Acetyl-5-Fluorouracil: Implications for its Rearrangements during Hydrolysis and upon Heating," Pharm. Res., 10 (1993) 905-912.
56. Sloan, K.B., Getz, J.J., Beall, H.D., Pranker, R.J., "Transdermal Delivery of 5-Fluorouracil (5-FU) by 1-Alkylaminocarbonyl-5-FU Prodrugs through Hairless Mouse Skin: Physicochemical Characterization of Prodrugs and Correlations with Transdermal Delivery," Int. J. Pharm., 93 (1993) 27-36.
57. Beall, H.D., Getz, J.J., and Sloan, K.B., "The Estimation of Relative Water Solubility for Prodrugs that are Unstable in Water," Int. J. Pharm., 93 (1993) 37-47.
58. Getz, J.J., Pranker, R.J., Sloan, K.B., "Mechanism of Hydrolysis of O- Imidomethyl Derivatives of Phenols," J. Org. Chem., 58 (1993) 4913-4918.
59. Sloan, K.B., Perrin, J.H., Comments Concerning: "Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs," J. Pharm. Sci., 83 (1994) 1066.
60. Beall, H.D., Pranker, R., Sloan, K.B., "Transdermal Delivery of 5-Fluorouracil (5-FU) Through Hairless Mouse Skin by 1-Alkyloxycarbonyl-5-FU Prodrugs: Physicochemical Characterization of Prodrugs and Correlations with Transdermal Delivery," Int. J. Pharm., 111 (1994) 223-233.
61. Patel, J.U., Pranker, R.J., Sloan, K.B., "A Prodrug Approach to Increasing the Oral Potency of a Phenolic Drug. Part 1. Synthesis, Characterization and Stability of an O-Imidomethyl Derivative of 17 β -Estradiol," J. Pharm. Sci., 83 (1994) 1477-1481.
62. Patel, J.U., Katovich, M.J., Sloan, K.B., Curry, S.H., Pranker, R.J., "A Prodrug Approach to Increasing the Oral Potency of a Phenolic Drug. Part 2. Pharmacodynamics and Preliminary Bioavailability of an Orally Administered O-Imidomethyl Derivative of 17 β -Estradiol," J. Pharm. Sci., 84 (1995) 174-178.
63. Beall, H.D., Pranker, R.J., Sloan, K.B., "1-Alkylcarbonyl- 5-fluorouracil Prodrugs: Synthesis, Thermal and Hydrolytic Stability," Drug Dev. Ind. Pharm., 22 (1996) 85-90.
64. Srinivasan, V., Wielbo, D., Simpkins, J., Karlix, J., Sloan, K., Tebbett, I., "Analgetic and Immunomodulatory Effects of Codeine and Codeine 6-Glucuronide," Pharm. Res., 13 (1996) 296-300.
65. Beall, H.D., Sloan, K.B., "Transdermal Delivery of 5-Fluorouracil (5-FU) by 1-Alkylcarbonyl-5-FU Prodrugs; Int. J. Pharm., 129 (1996) 203-210.

66. Beall, H.D., Prankerd, R.J., Sloan, K.B., "1,3-Bisalkylcarbonyl- and 3-Alkylcarbonyl-5-fluorouracil Prodrugs: Synthesis, Thermal and Hydrolytic Stability," Drug Dev. Ind. Pharm., 23 (1997) 517-525.
67. Patrick, A.I., Beall, H.D., Gilroy, P., Sloan, K.B., "Effect of Vehicles on Topical Delivery of 5-Fluorouracil (5FU) by 1-Acyl-5FU Prodrugs", Int. J. Pharm., 154 (1997) 39-48.
68. Sloan, K.B., Taylor, H.E., Hamilton, J.C., "Alcohol Flux and Effect on the Delivery of Theophylline from Propylene Glycol", Int. J. Pharm., 156 (1997) 17-26.
69. Taylor, H.E., Sloan, K.B., "1-Alkylcarbonyloxymethyl Prodrugs of 5-Fluorouracil (5FU): Synthesis, Physicochemical Properties and Topical Delivery of 5FU, "J. Pharm. Sci., 87 (1998) 15-20.
70. Kerr, D., Roberts, W., Tebbett, I., Sloan, K.B., "7-Alkylcarbonyloxymethyl Prodrugs of Theophylline: Topical Delivery of Theophylline", Int. J. Pharm., 167 (1998) 37-48.
71. Sloan, K.B., Beall, H.D., Taylor, H.E., Getz, J.J., Villanueva, R., Nipper, R., Smith, K., "Transdermal Delivery of Theophylline from Alcohol Vehicles", Int. J. Pharm., 171 (1998) 185-193.
72. Caram, L., Doeleman, M., Roberts, W.J., Prankerd, R.J., Perrin, J.H., Underberg, W.J., Sloan, K.B., "Synthesis of 1-and 3-Arylcarbonyl Derivatives of 5-Fluorouracil, "J.Het. Chem., 36 (1999) 397-401.
73. Roberts, W.J., Sloan, K.B., "Correlation of Aqueous and Lipid Solubilities with Flux for Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine, A Potts-Guy Approach," J. Pharm. Sci., 88 (1999) 515-522.
74. Roberts, W.J., Sloan, K.B., "Prediction of Transdermal Flux of Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine Using a New Series/Parallel Model," J. Pharm. Sci., 89, (2000) 1415-1431.
75. Sloan, K.B., DellaVecchia, S., Estes, J., Roberts, W.J., "7-Alkylcarbonyl and 7-Alkyloxycarbonyl Prodrugs of Theophylline: Topical Delivery of Theophylline", Int. J. Pharm., 205 (2000) 53-63.
76. Beall, H.D., Sloan, K.B., "Topical Delivery of 5-Fluorouracil (5-FU) by 3-Alkylcarbonyl-5-FU Prodrugs", Int. J. Pharm., 217 (2001) 127-137.
77. Roberts, W.J., Sloan, K.B., "Application of the Transformed Potts-Guy Equation to in vivo Human Skin Data", J. Pharm. Sci., 90 (2001) 1318-1323.

78. Beall, H.D., Sloan, K.B., "Topical Delivery of 5-Fluorouracil (5-FU) by 1, 3-Bisalkylcarbonyl-5-FU Prodrugs", Int. J. Pharm., 231 (2002) 43-49.
79. Roberts, W.J., Sloan, K.B., "Synthesis of 3-Alkylcarbonyloxymethyl Derivatives of 5-Fluorouracil," J. Het. Chem., 39 (2002) 905-910.
80. Sloan, K.B., Wasdo, S., Ezike-Mkparu, U., Murray, T.J., Nichels, D., Singh, S., Shanks, T., Tovar, J., Ulmer, K. and Warranis, R., "Topical Delivery of 5-Fluorouracil (5-FU) and 6-Mercaptopurine (6-MP) by their Alkylcarbonyloxymethyl (ACOM) Prodrugs from Water: Vehicle Effects on Design of Prodrugs,' Pharm. Res., 20 (2003) 639-645.
81. Roberts, W.J., Sloan, K.B., "Topical Delivery of 5-Fluorouracil (5-FU) by 3-Alkylcarbonyloxymethyl-5-FU Prodrugs," J. Pharm. Sci., 92 (2003) 1028-1036.
82. Sloan, K.B., Wasdo, S., "Design for Topical Delivery: Prodrugs Can Make the Difference," Med. Res. Rev., 23 (2003) 763-793.
83. Wasdo, S.C., Sloan, K.B., "Topical Delivery of a Model Phenolic Drug: Alkyloxycarbonyl Prodrugs of Acetaminophen", Pharm. Res., 21 (2004) 940-946.
84. Majumdar, S., Sloan, K.B., "Synthesis, Hydrolysis and Dermal Delivery of N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) Derivatives of Phenol, Imide and Thio Containing Drugs," Bioorg. Med. Chem. Lett., 16 (2006) 3590-3594
85. Majumdar, S., Sloan, K.B., "Practical Syntheses of N-Alkyl-N-alkyloxycarbonylaminomethyl Prodrugs of Acetaminophen, Theophylline and 6-Mercaptopurine," Synth. Commun., 36(2006)3537-3548
86. Thomas, J.D., Sloan, K.B., "Reaction of Alkylcarbonyloxymethyl Halides with Phenols: Reevaluating the Influence of Steric Hindrance," Tetrahedron Lett., 47 (2006) 8785-8787
87. Majumdar, S., Juntunen, J., Sivendran, S., Bharti, N., Sloan, K.B., "Synthesis of Soft Alkyl Phenolic Ether Prodrugs using Mitsunobu Chemistry," Tetrahedron Lett., 47 (2006) 8981-8982.
88. Sloan, K.B., Wasdo, S.C., Rautio, J., "Design for Optimized Topical Delivery: Prodrugs and a Paradigm Change," Pharm. Res., 23(2006)2729-2747
89. Majumdar, S., Thomas, J.D., Wasdo, S.C., Sloan, K.B., "The Effect of Water Solubility of Solutes on their Flux Through Human Skin in Vitro." Int. J. Pharm., 329(2007)25-36.

90. Thomas, J.D., Sloan, K.B., "Overcoming Steric Effects in the Coupling Reaction of Alkyloxycarbonyloxymethyl (AOCOM) Halides with Phenols: An Efficient Synthesis of AOCOM Phenolic Prodrugs," Tetrahedron Lett., 48 (2007) 109-112.
91. Majumdar, S., Sloan, K.B., "Topical Delivery of N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) Prodrugs of Theophylline (ThH)," Int. J. Pharm., 332 (2007) 64-71.
92. Majumdar, S., Sloan, K.B., "N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) Prodrugs of Carboxylic Acid Containing Drugs," Bioorg. Med. Chem. Lett., 17 (2007) 1447-1450.
93. Zhang, G., Moore, D.J., Sloan, K.B., Flach, C.R., Mendelsohn, R., "Imaging the Prodrug-to-Drug Transformation of a 5-Fluorouracil Derivative in Skin by Confocal Raman Microscopy," J. Invest. Dermatol., 127 (2007) 1205-1207
94. Majumdar, S., Sloan, K.B., "Synthesis and Topical Delivery of N-Alkyl-N-alkyloxycarbonylaminomethyl Prodrugs of a Model Phenolic Drug: Acetaminophen," Int J.Pharm., 337 (2007) 48-55.
95. Thomas, J., Majumdar, S., Wasdo, S., Majumdar, A., Sloan, K.B., "The Effect of Water Solubility of Solutes on their Flux through Human Skin *in vitro*: An Extended Flynn Database Fitted to the Roberts-Sloan Equation," Int. J. Pharm., 339 (2007) 157-167.
96. Majumdar, S., Spaeth, M.M., Sivendran, S., Juntunen, J., Thomas, J.D., Sloan, K.B., " α -(1H-Imidazol-1-yl)alkyl (IMIDA) Carboxylic Acid Esters as Prodrugs of Carboxylic Acid Containing Drugs," Tetrahedron Lett., 48 (2007) 4609-4611.
97. Thomas, J., Sloan, K.B., "In Vitro Evaluation of Alkylcarbonyloxymethyl (ACOM) Ethers as Novel Prodrugs of Phenols for Topical Delivery: ACOM Prodrugs of Acetaminophen," Int. J. Pharm., 346 (2007) 80-88.
98. Majumdar, S., Sloan, K.B., "Topical Delivery of Drugs as Prodrugs using the N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) Promoiety," Pharm. Tech. Eur., Dec. (2007) 33-35.
99. Juntunen, J., Majumdar, J. Sloan, K.B., "The Effect of Water Solubility of Solutes on Their Flux Through Human Skin *in vitro*: A Prodrug Database Integrated into the Extended Flynn Databases," Int. J. Pharm., 351(2008) 92-103.
100. Thomas, J.D., Sloan, K.B., "Reaction of α (n-Alkylcarbonyloxy)alkyl (ACOA) Halides with 4-Hydroxyacetanilide and 2,2,5,7,8-Pentamethyl-6-chromanol: the Effect of Steric Hindrance on Reaction Path," Synthesis (2008) 272-278.

101. Wasdo, S., Juntunen, J., Devarajan, H., Murray, T., Nichels, D., Singh, S., Shanks, J., Ulmer, K., Sloan, K.B., "Modeling of Flux through Silicone Membranes from Water," *Eur. J. Pharm. Sci.*, 34(2008) 321-332.
102. Wasdo, S.C., Juntunen, J., Devarajan, H., Sloan, K.B., "A Comparison of the Fit of Flux through Hairless Mouse Skin to Three Model Equations," *Int. J. Pharm.* 366(2009) 65-73.
103. Thomas, J.D., Sloan, K.B., "Evaluation of alkyloxycarbonyloxymethyl (AOCOM) ethers as novel Prodrugs of Phenols for Topical Delivery: AOCOM Prodrugs of Acetaminophen," *Int. J. Pharm.*, 371(2009) 25-32.
104. Wasdo, S.C., Juntunen, J., Devarajan, H., Sloan, K.B., "A Correlation of Flux through a Silicone Membrane with Flux through Hairless Mouse Skin and Human Skin in vitro," *Int. J. Pharm.*, 373(2009) 62-67.
105. Thomas, J.D., Majumdar, S., Sloan, K.B., "Soft Alkyl Ethers of a Model Phenolic Drug: The Effect of Incorporation of Ethylene Glycol Groups on Transdermal Delivery," submitted.

BOOK CHAPTERS AND BOOKS

1. Sloan, K.B., "The Use of Solubility Parameters of Drug and Vehicle to Describe Skin Transport," in Topical Drug Delivery Formulations. Edited by Osborne, D.W., and Amann, A.H., New York, N.Y., Marcel Dekker, Inc., 1990, pp 245-270.
2. Sloan, K.B., "Functional Group Considerations in the Development of Prodrug Approaches to solving Topical Delivery Problems," in Prodrugs: Topical and Ocular Drug Delivery. Edited by Sloan, K.B., New York, N.Y., Marcel Dekker, Inc., 1992, pp 17-116.
3. Sloan, K.B., "Use of Solubility Parameters from Regular Solution Theory to Describe Partitioning Driven Processes," in Prodrugs: Topical and Ocular Drug Delivery. Edited by Sloan, K.B., New York, N.Y., Marcel Dekker, Inc., 1992, pp 179-204.
4. Sloan, K.B., Editor, Prodrugs: Topical and Ocular Drug Delivery, New York, N.Y., Marcel Dekker, Inc., 1992, 313 p.
5. Arndt, K.A., Mendenhall, P.V., Sloan, K.B., and Perrin, J.H., "Pharmacology of Topical Therapy," in Dermatology and General Medicine. Edited by Fitzpatrick, T.B., Eisen, A.Z., Wolff, K., Freedberg, I.M., Austen, K.F., 4th Edition, New York, N.Y., McGraw-Hill, 1993.
6. Sloan, K.B., Araujo, A.E., Flowers, F.P., "Therapeutic Interventions with Topical Corticosteroids," in Cutaneous Medicine and Surgery. An Integrated Program in Dermatology. Edited by Arndt, K.A., Le Boit, P.E., Robinson, J.K., Wintroub, B.U., Philadelphia, PA, W.B. Saunders Company, 1995.
7. Sloan, K.B., Wasdo, S.C. "The Role of Prodrugs in Penetration Enhancement", in Percutaneous Penetration Enhancers, Smith, E., Maibach, H., ed. CRC Press, 2006. pp 51-64.
8. Sloan, K.B., Wasdo, S.C. "Topical Delivery Using Prodrugs", in Prodrugs: Challenges and Rewards, Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, K., Tilley, J.W. Maag, H., ed. AAPS Press, 2007. pp 83-123.
9. Sloan, K.B., Wasdo, S.C., "Percutaneous Absorption of Prodrugs and Soft Drugs," in Dermal Absorption and Toxicity Assessment, Roberts, M. Walters, K., ed., 2nd Edition, New York, NY, Marcel Debker, Inc., 2008, 589-606.

ABSTRACTS

1. Waranis, R.P., Siver, K.G., Sloan, K.B., "The Solubility Parameter of Vehicles as a Predictor of Vehicle Effects on the Diffusion of 6-Mercaptopurine," Pharm. Res., 3 (1986) 62 S.
2. Koch, S.A.M., Sloan, K.B., "N-Mannich Base Prodrugs of 5-Fluorocytosine as Topical Delivery Enhancers," Pharm. Res., 3 (1986) 24 S.
3. Waranis, R.P., Sloan, K.B., "Interaction of the Effects of Vehicles and Prodrug Properties on the Delivery of 6-Mercaptopurine Through Skin," Pharm. Res., 4 (1987) S-15.
4. Saab, A., Sloan, K.B., "The Effect of Aminomethyl (N-Mannich Base) Derivatives on the Ability of S⁶-Pivaloyloxymethyl-6-Mercaptopurine Prodrugs to Deliver 6-Mercaptopurine through Skin," Pharm. Res., 5 (1988) S-81.
5. Siver, K., Sloan, K.B., "Alkylation of 6-Mercaptopurine (6-MP) with N-Alkyl-N-alkoxycarbonylaminomethyl chlorides: S⁶ - (N-Alkyl-N-alkoxycarbonylaminomethyl)-6-MP Prodrug Effect on the Dermal Delivery of 6-MP," Pharm. Res., 5(1988) S-46.
6. Patel, J.U., Curry, S.H., Sloan, K.B., "Synthesis, Analysis and Stability of a Prodrug of 17 β -Estradiol," Pharm. Res., 6 (1989) S-145.
7. Sherertz, E.F., McTiernan, R.G., Sloan, K.B., "Epidermal Barrier Function in Rats During Chronic Ethanol Administration," J. Invest. Dermatol., 92 (1989) 517.
8. Beall, H.D., Sloan, K.B., "Evaluation of a Series of 1-Acylated Derivatives of 5-Fluorouracil (5-FU). Ability of Prodrugs to Deliver 5-FU Through Skin," Pharm. Res., 7 (1990) S-64.
9. Patel, J.U., Pranker, R.J., Katovich, M.J., Sloan, K.B., "Prodrug Approach to Improvement of the Oral Bioavailability of Compounds Undergoing First Pass Effect," Pharm. Res., 8 (1991) S-222.
10. Beall, H.D., Getz, J.J., Sloan, K.B., "Comparison of Three Different Types of 1-Acyl prodrugs of 5-Fluorouracil (5-FU) for their Abilities to Deliver 5-FU through Hairless Mouse Skin," Pharm. Res., 8 (1991) S-77.
11. Patel, J.U., Pranker, R.J., Katovich, M.J., Sloan, K.B., "A Comparison of the Oral Potencies of a Prodrug of 17 β -Estradiol in Ovariectomized Rats," J. Clin. Pharmacol., 31 (1991) 870.

12. Beall, H.D., Sloan, K.B., "The Effect of Degree of Substitution on the Abilities of N-Acyl Prodrugs of 5-Fluorouracil (5-FU) to Deliver 5-FU Through Hairless Mouse Skin," Pharm. Res., 9 (1992) S-102.
13. Patel, J.U., Sloan, K.B., Katovich, M.J., Curry, S.H., Pranker, R.J., "Pharmacokinetic-Pharmacodynamic Evaluation of a Prodrug Designed to Improve Oral Bioavailability of Compounds Susceptible to a Hepatic First Pass Effect," Pharm. Res., 9 (1992) S-7.
14. Getz, J.J., Pranker, R.J., Sloan, K.B. "Mechanism of Hydrolysis of O-Imidomethyl Derivatives of Phenols," Pharm. Res., 10 (1993) S-122.
15. Beall, H.D., Sloan, K.B., "Synthesis and Characterization of 3-Alkylcarbonyl-5-fluorouracil (5-FU) Prodrugs: Topical Delivery of 5-FU through Hairless Mouse Skin," Pharm. Res., 12 (1995) S-132.
16. Srinivasan, V., Wielbo, D., Sloan, K., Freiburger, B., Karlix, J., Simpkins, J., Tebbet, I., "Analgesic and Immunomodulatory Effects of Codeine and Codeine-6-glucuronide," Pharm. Res., 12 (1995) S-3.
17. Sloan, K., Beall, H., Taylor, H., Getz, J., Villanueva, R., Nipper, R., Smith, K., "Alcohol Flux and the Effects of Alcohols on the Transdermal Delivery of Theophylline," Pharm. Res., 13 (1996) S-251.
18. McKenzie, M., Brushwood, D., Pevonka, P., Delafuente, J., Doty, R., Gums, J., Hendeles, L., Hochhaus, G., Kimberlin, C., Millard, W., Russell, W., and Sloan, K., "New Doctor of Pharmacy Curriculum at the University of Florida: Planning and Process," Am. J. Pharm. Ed., 60 (1996) 104S.
19. Taylor, H.E., Sloan, K.B., "1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): Synthesis, Physicochemical Properties and Topical Delivery of 5-FU," Pharm. Res., 14 (1997) S-312.
20. Roberts, W.J., Sloan, K.B., "Correlation of Aqueous and Lipid Solubilities with Flux for Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine," Pharm. Res., 15 (1998) S-165.
21. Roberts, W.J., Sloan, K.B., "Prediction of Transdermal Flux of Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine Using the Solvatochromic Equation and a New Series/Parallel Model," Pharm. Res., 16 (1999) S-9 to S-10.
22. Roberts, W.J., Sloan, K.B., "3-ACOM Prodrugs of 5-FU: Topical Delivery of 5-Fluorouracil by 3-Alkylcarbonyloxymethyl Derivatives", AAPS Annual Meeting and Exposition, October 29, 2000: AAPS Pharm. Sci., 2 (2000) S1 abstract 382.

23. Wasdo, S., Sloan, K.B., "Topical Delivery of 5-Fluorouracil (5-FU) and 6-Mercaptopurine (6-MP) by their Alkylcarbonyloxymethyl (ACOM) Prodrugs from Water: Vehicle Effects on Design of Prodrugs," AAPS Annual Meeting Exposition, November 14, 2002: AAPS Pharm. Sci., 4 (2002) S1 abstract R6089.
24. Sloan, K.B., Wasdo, S.C., "Topical Delivery of a Model Phenolic Drug using Carbonate Prodrugs: Acetaminophen", AAPS Annual Meeting Exposition, October 28, 2003: AAPS Pharm. Sci., 5 (2003) S1 abstract T2217.
25. Majumdar, S., Thomas, J.D., Wasdo, S.C., Sloan, K.B., "The Effect of Water Solubility of Solutes on their Flux through Human Skin: The Extended and Edited Flynn Database," AAPS Annual Meeting Exposition, November 10, 2004: AAPS J., 6 (2004) S1 abstract W4250.
26. Thomas, J.D., Sloan, K., "Prediction of the Flux of Naproxen Prodrugs and Several Unrelated Compounds from Propylene Glycol through Human Skin in Vitro Using the Roberts-Sloan Equation," AAPS J., 7 (2005) S2 abstract R6095.
27. Majumdar, S., Sloan, K., "Prediction of the Flux of Sunscreens and Other Compounds from PG/Water through Human Skin in Vivo Using the Roberts-Sloan (RS) Equation," AAPS J., 7 (2005) S2 abstract R6075.
28. Majumdar, S., Sloan, K.B., "Topical Delivery of N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) Prodrugs of a Model Phenolic Drug: Acetaminophen," AAPS J., 8(2006)S2 abstract M1139.
29. Majumdar, S., Sloan, K.B., "Topical Delivery of N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) Prodrug of Theophylline," AAPS J., 8(2006)S2 abstract M1140.
30. Majumdar, S., Thomas, J., Spaeth, M., Majumdar, A., Sloan, K., "Prediction of the Flux of Prodrugs of Acetaminophen and Theophylline from IPM Through Hairless Mouse Skin in vitro Using the Roberts – Sloan Equation," AAPS J., 8(2006)S2 abstract M1141.
31. Spaeth, M., Majumdar, S., Sloan, K., topical "Delivery of 7-Alkyloxycarbonyl (AOC) Prodrugs of Theophylline," AAPS J., 8(2006)S2 abstract M1142.
32. Juntunen, J., Sloan, K., "Addition of in vitro Prodrug Skin Permeation Data to the Extended and Edited Flynn Database," AAPS J., 8(2006)S2 abstract M1190.
33. Majumdar, S., Spaeth, M., Sloan, K.B., " α -(1H-Imidazol-1-yl)alkyl (IMIDA) Carboxylic Acid Containing Drugs" AAPS J., 9(2007)S2 abstract m1116.

34. Juntunen, J., Devarajan, H., Wasdo, S., Sloan, K., "Modeling of Flux Through Polydimethyl Siloxane (PDMS) Membrane" AAPS J., 9(2007)S2 abstract T3224.
35. Devarajan, H., Wasdo, S.C., Juntunen, J., Sloan, K.B., "A Comparison of Fit to Three Model Equations of Data for Flux through Hairless Mouse Skin from Water," AAPS Annual Meeting, 2008, abstract T3034.
36. Wasdo, S.C., Juntunen, J., Devarajan, H., Sloan, K.B., "A Correlation of Flux through a Silicone Membrane with Flux through Hairless Mouse Skin and Human Skin in Vitro," AAPS Annual Meeting, 2008, abstract T3035.

MISCELLANEOUS PUBLICATIONS, PATENTS

1. Bodor, N., Sloan, K., and Hussain, A., "Novel, Transient, Pro-Drug Forms of L-DOPA," U.S. Patent 3,891,696, June 24, 1975; Chem. Abstr., 83 (1975) P193724.
2. Bodor, N., Sloan, K., and Hussain, A., "Novel, Transient, Pro-Drug Forms of L-DOPA Useful in the Treatment of Parkinson's Disease," U.S. Patent 3,939,253, February 7, 1976. Chem. Abstr., 84 (1976) P130508.
3. Bodor, N., and Sloan, K., "Novel, Transient, Pro-Drug Forms of Phenylbutazone and Oxyphenbutazone," U.S. Patent 3,957,803, May 18, 1976; Chem. Abstr., 85 (1976) P46671.
4. Bodor, N., Sloan, K., and Hussain, A., "Novel, Transient, Pro-Drug Form of L-DOPA," U.S. Patent 3,998,799, December 21, 1976; Chem. Abstr., 87 (1977) P53594.
5. Bodor, N., Sloan, K., and Kuo, Y.N., "A Method for Synthesizing Certain Selected Pro-Drug Forms of Theophylline," U.S. Patent 4,000,132, December 28, 1976; Chem. Abstr., 86 (1977) P190012.
6. Bodor, N., Sloan, K.B., and Hussain, A., "Novel, Transient, Pro-Drug Forms of L-DOPA," U.S. Patent 4,035,507, July 12, 1977; Chem. Abstr., 87 (1977) P184969.
7. Bodor, N., and Sloan, K., "Novel, Transient, Pro-Drug Forms of Phenylbutazone and Oxyphenbutazone," U.S. Patent 4,036,845, July 19, 1977; Chem. Abstr., 87 (1977) P152197.
8. Bodor, N., and Sloan, K., "Novel, Transient, Pro-Drug Forms of Xanthine Derivatives," U.S. Patent 4,061,753, December 6, 1977; Chem. Abstr., 87 (1977) P152278.
9. Bodor, N., Sloan, K.B., and Hussain, A., "Novel, Transient, Pro-Drug Forms of L-DOPA," U.S. Patent 4,065,566, December 27, 1977; Chem. Abstr., 87 (1977) P53594.
10. Bodor, N., and Sloan, K.B., "Pro-Drugs for the Improved Delivery of Certain Anti-Inflammatory Steroids", U.S. Patents 4,069,322, January 1, 1978; Chem. Abstr., 89 (1978) P75419.
11. Bodor, N., and Sloan, K.B., "Transient, Pro-Drug Forms of Phenylbutazone," U.S. Patent 4,117,232, September 26, 1978; Chem. Abstr., 85 (1976) P46671.

12. Bodor, N., and Sloan, K.B., "1,2-Diphenyl-3,5-Ditrifluoroacetyloxy-4-butyl-5-hydroxy-3-pyrazoline," U.S. Patent 4,139,709, February 13, 1979; Chem. Abstr., 85 (1976) P46671.
13. Stella, V.J., and Sloan, K.B., "Derivatives of 5,5-Diphenylhydantoin Exhibiting Enhanced Solubility and Therapeutic Use Thereof," U.S. Patent 4,163,058, July 31, 1979; Chem. Abstr., 91 (1979) P193312.
14. Bodor, N., and Sloan, K.B., "Novel, Transient, Pro-Drug Forms of Phenylbutazone and Oxyphenbutazone in Compositions and Methods of Use," U.S. Patent 4,169,147, September 25, 1979; Chem. Abstr., 85 (1976) P46671.
15. Sloan, K.B., "Pro-Drugs for the Improved Delivery of Non-Steroidal, Anti-Inflammatory Agents," U.S. Patent 4,206,220, June 3, 1980; Chem Abstr., 93 (1980) P8017.
16. Bodor, N., and Sloan, K.B., "Anti-Acne and Anti-Seborrhea Pro-Drug Derivatives of Progesterone," U.S. Patent 4,213,978, July 22, 1980; Chem. Abstr., 94 (1981) P84376.
17. Bodor, N., and Sloan, K.B., "Novel, Transient, Pro-Drug Forms of Xanthine Derivatives and Their Use as Topical Anti-Inflammatory Agents," U.S. Patent 4,275,064, June 23, 1981; Chem. Abstr., 87 (1977) P152278.
18. Bodor, N., and Sloan, K.B., "Pro-Drugs for Improved Bioavailability of Certain ⁴-3-Ketosteroid Sex Hormones," U.S. Patent 4,268,441, May 19, 1981.
19. Bodor, N., and Sloan, K.B., "Esteramide Pro-Drugs of Anti-Inflammatory Corticosteroids," U.S. Patent 4,221,787, September 9, 1980; Chem. Abstr., 94 (1981) P47619.
20. Bodor, N., and Sloan, K.B., "Pro-Drugs for the Improved Delivery of Halogen-Containing Glucocorticosteroids," U.S. Patent 4,279,900, July 21, 1981; Chem. Abstr., 96 (1982) P6952.
21. Bodor, N., and Sloan, K.B., "Thiazolidine Pro-Drugs for the Improved Delivery of Anti-Inflammatory Corticosteroids," U.S. Patent 4,239,757, December 16, 1980; Chem. Abstr., 94 (1981) P192573.
22. Bodor, N., Sloan, K.B., and Pogany, S., "Novel Sympathomimetic Amine Pro- Drugs," U.S. Patent 4,313,956, February 2, 1982; Chem. Abstr., 96 (1982) P162444.
23. Bodor, N., Sloan, K.B., and Pogany, S., "Novel Dopa/Dopamine Pro-Drugs," U.S. Patent 4,311,706, January 19, 1982; Chem. Abstr., 96 (1982) P200160.

24. Sloan, K.B., Bodor, N., and Pogany, S., "Novel Pro-Drugs of Biologically Active Agents Containing Mercapto Groups," European Pat. Appl., EP 38,541, October 28, 1981; Chem. Abstr., 96 (1982) P181056.
25. Sloan, K.B., and Little, R.J., "Mannich-Base Hydroxamic Acid Pro-Drugs for the Improved Delivery of Non-Steroidal Anti-Inflammatory Agents," European Pat. Appl. EP 39,051, November 4, 1981; Chem. Abstr., 96 (1982) P104087.
26. Bodor, N., Sloan, K.B., and Pogany, S., "Novel Derivatives of Bioaffecting Phenolic Compounds," European Pat. Appl., EP 46,270, February 24, 1982; Chem. Abstr., 97 (1982) P23445.
27. Bodor, N., Sloan, K.B., and Pogany, S., "Novel Intropic Pro-Drugs", U.S. Patent 4,340,603, July 20, 1982; Chem. Abstr., 97 (9182) P222949.
28. Sloan, K.B., "Soft Tertiary Amine Esters as a Pro-Drug Delivery System for Carboxylic Acid Containing Drugs," European Pat. Appl., EP 51,278, May 12, 1982; Chem. Abstr., 97 (1982) P144855.
29. Sloan, K.B., "Pyridylmethyl Esters of Carboxylic Acids," U.S. Patent 4, 376,767, March 18, 1983; Chem. Abstr., 97 (1982) P216007.
30. Stella, V.J., and Sloan, K.B., "5,5-Diphenylhydantoin," U.S. Patent 4,260,769, April 7, 1981; Chem. Abstr., 91 (1979) P193312.
31. Sloan, K.B., Bodor, N.S., and Pogany, S., "Prodrugs of 6-Mercaptopurine and 6-Mercaptopurine Ribosides and Therapeutic Compositions and Methods Employing Them," U.S. Patent 4,443,435, April 17, 1984; Chem. Abstr., 101 (1984) p152270.
32. Sloan, K.B., "Soft Alkylaminoalkyl Derivatives of Amides, Imides and Amines for the Improved Delivery of Drugs Through Topical Membranes," U.S. Patent 4, 845,081, July 4, 1989; Chem Abstr., 112 (1990) P104877.
33. Sloan, K.B., "Prodrugs of Biologically Active Hydroxyaromatic Compounds," U.S. Patent 5,001,115, March 19, 1991; Chem Abstr., 115 (1991) P49083.
34. Sloan, K.B., and Beall, H.D., "Topical 5-Fluorouracil Prodrug Composition and Method," U.S. Patent 5, 610, 160 March 11, 1997.

PRESENTATIONS WITHOUT ABSTRACTS

1. Sloan, K.B., Selk, S., Caldwell, L., Bodor, N., Little, R., "Antiinflammatory Steroids: A Prodrug Approach to Increasing the Therapeutic Index," Division of Medicinal Chemistry, American Chemical Society, 179th Annual Meeting; Houston, Texas; March, 1980; Abstract 12.
2. Sloan, K.B., Hashida, M., Alexander, J., Bodor, N., Higuchi, T., "Prodrugs of 6-Mercaptopurine," Basic Pharmaceutics Section, American Pharmaceutical Association Academy of Pharmaceutical Sciences, 31th National Meeting; Orlando, Florida; November, 1981; Abstract 28, page 85.
3. Sloan, K.B., "Hydroxymethyl and Acyloxymethyl Derivatives of Theophylline," Fifteenth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1982.
4. Sloan, K.B., "The Effect of the Incorporation of Amine Groups into Prodrugs of Polar Drugs," Seventeenth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1984.
5. Sloan, K.B., "Prodrug Approaches to Enhanced Delivery of Drugs Containing the Cytosine Moiety," Eighteenth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1985.
6. Sloan, K.B., "The Use of Solubility Parameters of Drug and Vehicle to Predict Flux Through Skin," Nineteenth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1986.
7. Sloan, K.B., "The Effect of Vehicles on the Delivery of 6-Mercaptopurine Through Hairless Mouse Skin," Twentieth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1987.
8. Sloan, K.B., "N-Mannich Base Prodrugs of 6-Mercaptopurine: Improved Dermal Delivery of 6-Mercaptopurine," Twenty-First Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1988.
9. Sloan, K.B., "The Effect of the Structure of an Aminomethyl Promoiety on the Ability of 6-Acyloxymethyl-6-Mercaptopurine to Deliver 6-Mercaptopurine Through Hairless Mouse Skin," Twenty-Second Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1989.

10. Sloan, K.B., "A Comparison of the Effect of Formulations and a Prodrug on the Delivery of 5-FU Through Hairless Mouse and Human Skin," Twenty-third Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1990.
11. Sloan, K.B., "Solubility Parameters as a Tool to Predict Flux," American Association of Pharmaceutical Scientists, 4th Annual Meeting; Atlanta, Georgia; October, 1989; A83.
12. Sloan, K.B., "N-Acyl Derivatives of 5-Fluorouracil; Enhanced Transdermal Delivery," Twenty-Fourth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1991.
13. Sloan, K.B., "Prodrugs for Topical Delivery," 1991 Gordon Research Conference on Barrier Function of Mammalian Skin; Plymouth State College, Plymouth, New Hampshire.
14. Sloan, K.B., "Dermal and Transdermal Delivery of Drugs Utilizing a Prodrug Approach," Wyeth-Ayerst Research, Rouses Point, New York; January 24, 1992.
15. Sloan, K.B., "Benzamidomethyl and Imidomethyl Ethers of Phenols as Prodrugs," Twenty-Fifth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1992.
16. Sloan, K.B., "Topical Steroids," Dermatology Grand Rounds, University of Florida, Gainesville, Florida; July 30, 1992.
17. Sloan, K.B., "Structure of 3-Acyl-5-fluorouracils: Implications for its Rearrangements during Heating and Upon Hydrolysis," Twenty-Sixth Annual Higuchi Research Seminar; Lake Ozark, Missouri; March, 1993.
18. Sloan, K.B., "Use of Prodrugs to Enhance Topical Delivery: 5-Fluorouracil," Calgon Vestal Laboratories, Saint Louis, Missouri, March 18, 1993.
19. Sloan, K.B., "O-Imidomethyl Derivatives of Phenols: Mechanism of Hydrolysis and Application to Estradiol," Twenty-Seventh Annual Higuchi Research Seminar; Lake Ozark, Missouri, March, 1994.
20. Sloan, K.B., "Prodrugs for Enhanced Topical Delivery," Unilever Research, U.S., Edgewater, New Jersey; June 7, 1994.
21. Patrick, A.I., Sloan, K.B., "Vehicle Effects on Transdermal Delivery of 5-Fluorouracil (5-FU) through Hairless Mouse Skin by 1-Alkylcarbonyl-5-FU Prodrugs," the Merck Undergraduate Research Scholar Program Symposium, the American Association of Pharmaceutical Scientists, 9th Annual Meeting; San Diego, California; November 6, 1994.

22. Sloan, K.B., "The Effect of Alcohol Vehicles on the Transdermal Delivery of Theophylline," Twenty-Eighth Annual Higuchi Research Seminar; Lake Ozark, Missouri, March, 1995.
23. Sloan, K.B., "Structure/Potency of Steroids," Dermatology Grand Rounds, University of Florida, Gainesville, Florida; September 7, 1995.
24. Sloan, K.B., "The Effect of Position of Substitution on the Ability of Alkylcarbonyl Derivatives of 5-FU to Enhance Topical Delivery", Twenty-Ninth Annual Higuchi Research Seminar, Lake Ozark, Missouri, March 1996.
25. Sloan, K.B., "Structure of 1- and 3-Arylcabonyl-5-FU Derivatives: Effect on Hydrolytic and Thermal Stability," Thirtieth Annual Higuchi Research Seminar, Lake Ozark, Missouri, March, 1997.
26. Kerr, D.P., Sloan, K.B., "Evaluation of Acyloxymethyl Promoieties to Enhance Topical Delivery" The Merck Research Scholars Program Symposium, The American Association of College of Pharmacy, Indianapolis, Indiana, July 15, 1997.
27. Sloan, K.B., "Topical Delivery of 5-Fluorouracil Using 1-Alkylcarbonyloxymethyl Prodrugs", Thirty First Annual Higuchi Research Seminar, Lake Ozark, Missouri, March, 1998.
28. Sloan, K.B., "Correlation of Aqueous and Lipid Solubilities with Flux for Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine", Thirty Second Annual Higuchi Research Seminar, Lake Ozark, Missouri, March, 1999.
29. Sloan, K.B., "Topical Steroids", Dermatology Grand Rounds, University of Florida, Gainesville, Florida, August 5, 1999
30. Sloan, K.B., "Prediction of Transdermal Flux of Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine Using the Solvatochromic Equation and a New Series/Parallel Model, "Thirty Third Annual Higuchi Research Seminar, Lake Ozark, Missouri, March, 2000.
31. Sloan, K.B., "Predicting Topical Delivery", Dermatology Grand Rounds, University of Florida, Gainesville, Florida, August 10, 2000.
32. Sloan, K.B., "3-ACOM Prodrugs of 5-FU,: Topical Delivery of 5-Fluorouracil by 3-Alkylcarbonyloxymethyl Derivatives,". Thirty Fourth Annual Higuchi Research Seminar Lake Ozark, Missouri, March 11-14, 2001.

33. Sloan, K.B., "Topical Steroids", Dermatology Grand Rounds, University of Florida; Gainesville, Florida, August 2, 2001.
34. Sloan, K.B., "Basics of Prodrugs", AAPS National Meeting, October 23, 2001; Denver, Colorado.
35. Sloan, K.B., "Topical Delivery of 5-Fluorouracil (5-FU) and 6-Mercaptopurine (6-MP) by their Alkylcarbonyloxymethyl (ACOM) Prodrugs from Water: Vehicle Effects on Design of Prodrugs. Thirty-Fifth Annual Higuchi Research Seminar, Lawrence, KS, May 15, 2002.
36. Sloan, K.B., "Whatever Happened to Prodrugs and Soft Drugs-Have you been Watching the Evening News?" August 13, 2002; Pfizer, Ann Arbor, Michigan.
37. Sloan, K.B. "Topical Delivery-Water Solubility is as Important as Lipid Solubility" August 13, 2002; Pfizer, Ann Arbor, Michigan.
38. Sloan, K.B. "Topical Delivery of a Model Phenolic Drug Using Carbonate Prodrugs". Thirty Sixth Annual Higuchi Research Seminar, Lawrence, KS, May 6, 2003.
39. Sloan, K.B., "Topical Delivery-Water Solubility is Important" December 19, 2003, Inspire Pharmaceuticals Durham, NC.
40. Sloan, K.B. "The Effect of Water Solubility of Solutes on Their Flux through Human Skin", Thirty Seventh Annual Higuchi Research Seminar, Lawrence KS, May 5, 2004.
41. Majumdar, S., Sloan, K.B., "Investigation of N-Alkyl-N-alkyloxycarbonylaminomethyl Promoiety as Novel Bioreversible Prodrugs for Phenol and Imide Containing Drugs." 231st ACS National Meeting, March 2006: MEDI-239.
42. Thomas, J.D., Sloan, K.B., "Evaluation of Alkyloxycarbonyloxymethyl and Alkylcarbonyloxymethyl Prodrugs as Permeation-Enhancing Derivatives of Phenol Containing Drugs." 231st ACS National Meeting, March 2006: MEDI-320.
43. Thomas, J.D., Sloan, K.B., "Coupling Reaction of Alkylcarbonyloxymethyl Halides with Phenols: Reevaluating the Influence of Steric Hindrance." 231st ACS National Meeting, March 2006: ORGN-102.
44. Majumdar, S., Sloan, K.B., "Mechanism of Hydrolysis of N-Alkyl-N-alkyloxycarbonylaminomethyl and N-Aryl-N-alkyloxycarbonylaminomethyl Derivatives of Phenols and Carboxylic Acids." 231st ACS National Meeting, March 2006: ORGN-103.

45. Sloan, K., "Predictors of Topical Drug Delivery," October 26, 2007. Merial Limited, North Brunswick, NJ.

05/29/09